Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate

References

• American Academy of Sleep Medicine. International Classification of Sleep Disorders – Third Edition,Text Revision (ICSD-3-TR). Darien, IL: American Academy of Sleep Medicine; 2023.
   Google Scholar
• Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30(5):369–379. doi:10.1007/s40263-016-0337-4
   PubMed Web of Science ®Google Scholar
• Billiard M, Sonka K. Idiopathic hypersomnia. Sleep Med Rev. 2016;29:23–33. doi:10.1016/j.smrv.2015.08.007
   PubMed Web of Science ®Google Scholar
• Wasling HB, Bornstein A, Wasling P. Quality of life and procrastination in post-H1N1 narcolepsy, sporadic narcolepsy and idiopathic hypersomnia, a Swedish cross-sectional study. Sleep Med. 2020;76:104–112. doi:10.1016/j.sleep.2020.10.014
   PubMed Web of Science ®Google Scholar
• Ozaki A, Inoue Y, Nakajima T, et al. Health-related quality of life among drug-naive patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. J Clin Sleep Med. 2008;4(6):572–578. doi:10.5664/jcsm.27352
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014;15(5):502–507. doi:10.1016/j.sleep.2014.01.015
   PubMed Web of Science ®Google Scholar
• Acquavella J, Mehra R, Bron M, Suomi JMH, Hess GP. Prevalence of narcolepsy, other sleep disorders, and diagnostic tests from 2013–2016: insured patients actively seeking care. J Clin Sleep Med. 2020;16(8):1255–1263. doi:10.5664/jcsm.8482
   PubMed Web of Science ®Google Scholar
• Junnarkar G, Allphin C, Profant J, et al. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. Expert Opin Drug Discov. 2022;17(2):109–119. doi:10.1080/17460441.2022.1999226
   PubMed Web of Science ®Google Scholar
• Xywav®. (Calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution, CIII [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; 2023.
   Google Scholar
• US Food and Drug Administration. Quantitative labeling of sodium, potassium, and phosphorus for human over-the-counter and prescription drug products. Guidance for industry; 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug. Accessed October 11, 2022.
   Google Scholar
• US Food and Drug Administration. Clinical review for Binosto, NDA 202344; 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202344Orig1s000MedR.pdf. Accessed February 28, 2023.
   Google Scholar
• Szarfman A, Kuchenberg T, Soreth J, Lajmanovich S. Declaring the sodium content of drug products. N Engl J Med. 1995;333(19):1291. doi:10.1056/NEJM199511093331917
   PubMed Web of Science ®Google Scholar
• Overeem S, Reading P, Bassetti CL. Narcolepsy. Sleep Med Clin. 2012;7:263–281. doi:10.1016/j.jsmc.2012.03.013
   Google Scholar
• Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57(11):2029–2033. doi:10.1212/WNL.57.11.2029
   PubMed Web of Science ®Google Scholar
• American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
   Google Scholar
• Lopez R, Doukkali A, Barateau L, et al. Test-retest reliability of the multiple sleep latency test in central disorders of hypersomnolence. Sleep. 2017;40(12). doi:10.1093/sleep/zsx164
   Web of Science ®Google Scholar
• Trotti LM, Staab BA, Rye DB. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med. 2013;9(8):789–795. doi:10.5664/jcsm.2922
   PubMed Web of Science ®Google Scholar
• Ruoff C, Pizza F, Trotti LM, et al. The MSLT is repeatable in narcolepsy type 1 but not narcolepsy type 2: a retrospective patient study. J Clin Sleep Med. 2018;14(1):65–74. doi:10.5664/jcsm.6882
   PubMed Web of Science ®Google Scholar
• Kim T, Lee JH, Lee CS, Yoon IY. Different fates of excessive daytime sleepiness: survival analysis for remission. Acta Neurol Scand. 2016;134(1):35–41. doi:10.1111/ane.12504
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 1999;22(6):757–765. doi:10.1093/sleep/22.6.757
   PubMed Web of Science ®Google Scholar
• Mutti C, Brunetti V, Figorilli M, et al. Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort. Neurol Sci. 2022;43(9):5563–5574. doi:10.1007/s10072-022-06210-9
   PubMed Web of Science ®Google Scholar
• Davidson RD, Biddle K, Nassan M, Scammell TE, Zhou ES. The impact of narcolepsy on social relationships in young adults. J Clin Sleep Med. 2022;18(12):2751–2761. doi:10.5664/jcsm.10212
   PubMed Web of Science ®Google Scholar
• Vignatelli L, D’Alessandro R, Mosconi P, et al. Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey. Sleep Med. 2004;5(5):467–475. doi:10.1016/j.sleep.2004.04.003
   PubMed Web of Science ®Google Scholar
• Rovere H, Rossini S, Reimao R. Quality of life in patients with narcolepsy: a WHOQOL-bref study. Arq Neuropsiquiatr. 2008;66(2a):163–167. doi:10.1590/S0004-282X2008000200004
   PubMed Web of Science ®Google Scholar
• Black J, Reaven NL, Funk SE, et al. The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings. Sleep Med. 2014;15(5):522–529. doi:10.1016/j.sleep.2014.02.001
   PubMed Web of Science ®Google Scholar
• Fronczek R, Arnulf I, Baumann CR, Maski K, Pizza F, Trotti LM. To split or to lump? Classifying the central disorders of hypersomnolence. Sleep. 2020;43(8). doi:10.1093/sleep/zsaa044
   PubMed Web of Science ®Google Scholar
• Vernet C, Arnulf I. Narcolepsy with long sleep time: a specific entity? Sleep. 2009;32(9):1229–1235. doi:10.1093/sleep/32.9.1229
   PubMed Web of Science ®Google Scholar
• Bruck D, Parkes JD. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data. J Neurol Neurosurg Psychiatry. 1996;60(5):576–578. doi:10.1136/jnnp.60.5.576
   PubMed Web of Science ®Google Scholar
• Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain. 1997;120(8):1423–1435. doi:10.1093/brain/120.8.1423
   PubMedGoogle Scholar
• Anderson KN, Pilsworth S, Sharples LD, Smith IE, Shneerson JM. Idiopathic hypersomnia: a study of 77 cases. Sleep. 2007;30(10):1274–1281. doi:10.1093/sleep/30.10.1274
   PubMed Web of Science ®Google Scholar
• Stevens J, Schneider LD, Husain AM, et al. Impairment in functioning and quality of life in patients with idiopathic hypersomnia: the real world idiopathic hypersomnia outcomes study (ARISE). Nat Sci Sleep. 2023;15:593–606. doi:10.2147/NSS.S396641
   PubMed Web of Science ®Google Scholar
• Whalen M, Roy B, Steininger T, Dronamraju N, Enson D. Patient perspective on idiopathic hypersomnia: impact on quality of life and satisfaction with the diagnostic process and management [poster 157]. Presented at: Annual Meeting of the Associated Professional Sleep Societies; Charlotte, NC; 2022.
   Google Scholar
• Whalen M, Roy B, Steininger T, Dronamraju N, Enson D. Physician perspective on idiopathic hypersomnia: awareness, diagnosis, and impact on patients [poster 156]. Presented at: Annual Meeting of the Associated Professional Sleep Societies; Charlotte, NC; 2022.
   Google Scholar
• Ohayon MM, Thorpy MJ, Carls G, et al. The Nexus Narcolepsy Registry: methodology, study population characteristics, and patterns and predictors of narcolepsy diagnosis. Sleep Med. 2021;84:405–414. doi:10.1016/j.sleep.2021.06.008
   PubMed Web of Science ®Google Scholar
• Lammers GJ, Bassetti CLA, Dolenc-Groselj L, et al. Diagnosis of central disorders of hypersomnolence: a reappraisal by European experts. Sleep Med Rev. 2020;52:101306. doi:10.1016/j.smrv.2020.101306
   PubMed Web of Science ®Google Scholar
• Poli F, Pizza F, Mignot E, et al. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep. 2013;36(2):175–181. doi:10.5665/sleep.2366
   PubMed Web of Science ®Google Scholar
• Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med. 2017;33:13–18. doi:10.1016/j.sleep.2016.04.004
   PubMed Web of Science ®Google Scholar
• Ben-Joseph RH, Saad R, Black J, et al. Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study. Sleep. 2023. doi:10.1093/sleep/zsad161
   PubMed Web of Science ®Google Scholar
• Saad R, Prince P, Taylor B, Ben-Joseph RH. Characteristics of adults newly diagnosed with idiopathic hypersomnia in the United States. Sleep Epidemiol. 2023. 18 July Online Ahead of Print. doi:10.1016/j.sleepe.2023.100059
   PubMedGoogle Scholar
• Miglis MG, Schneider L, Kim P, Cheung J, Trotti LM. Frequency and severity of autonomic symptoms in idiopathic hypersomnia. J Clin Sleep Med. 2020;16(5):749–756. doi:10.5664/jcsm.8344
   PubMed Web of Science ®Google Scholar
• Vernet C, Leu-Semenescu S, Buzare MA, Arnulf I. Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness. J Sleep Res. 2010;19(4):525–534. doi:10.1111/j.1365-2869.2010.00824.x
   PubMed Web of Science ®Google Scholar
• Arnulf I, Leu-Semenescu S, Dodet P. Precision medicine for idiopathic hypersomnia. Sleep Med Clin. 2019;14(3):333–350. doi:10.1016/j.jsmc.2019.05.007
   PubMed Web of Science ®Google Scholar
• Maski K, Mignot E, Plazzi G, Dauvilliers Y. Disrupted nighttime sleep and sleep instability in narcolepsy. J Clin Sleep Med. 2022;18(1):289–304. doi:10.5664/jcsm.9638
   PubMed Web of Science ®Google Scholar
• Schneider LD, Stevens J, Husain AM, et al. Symptom severity and treatment satisfaction in patients with idiopathic hypersomnia: the real world idiopathic hypersomnia outcomes study (ARISE). Nat Sci Sleep. 2023;15:89–101. doi:10.2147/NSS.S386021
   PubMed Web of Science ®Google Scholar
• Ong JC, Dawson SC, Mundt JM, Moore C. Developing a cognitive behavioral therapy for hypersomnia using telehealth: a feasibility study. J Clin Sleep Med. 2020;16(12):2047–2062. doi:10.5664/jcsm.8750
   PubMed Web of Science ®Google Scholar
• Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100. doi:10.1038/nrdp.2016.100
   PubMed Web of Science ®Google Scholar
• Avadel pharmaceuticals announces final FDA approval of LUMRYZ™ (sodium oxybate) for extended-release oral suspension as the first and only once-at-bedtime oxybate for cataplexy or excessive daytime sleepiness in adults with narcolepsy [press release]; 2023. Available from: https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-announces-final-fda-approval-lumryztm. Accessed May 1, 2023.
   Google Scholar
• Lumryz^TM (Sodium Oxybate) for Extended-Release Oral Solution, CIII [Prescribing Information]. Chesterfield, MO: Avadel CNS Pharmaceuticals; 2023.
   Google Scholar
• European Medicines Agency. Modafinil; 2011. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/modafinil#:~:text=Looking. Accessed February 2, 2022.
   Google Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881–1893. doi:10.5664/jcsm.9328
   PubMed Web of Science ®Google Scholar
• Lopez R, Arnulf I, Drouot X, Lecendreux M, Dauvilliers Y. French consensus. Management of patients with hypersomnia: which strategy? Rev Neurol. 2017;173(1–2):8–18. doi:10.1016/j.neurol.2016.09.018
   PubMedGoogle Scholar
• Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3):zsaa206. doi:10.1093/sleep/zsaa206
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022;21(1):53–65. doi:10.1016/S1474-4422(21)00368-9
   PubMed Web of Science ®Google Scholar
• Xyrem^® (Sodium Oxybate) Oral Solution, CIII [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2023.
   Google Scholar
• World Health Organization. Guideline: Sodium Intake for Adults and Children. Geneva, Switzerland: World Health Organization; 2012.
   Google Scholar
• Institute of Medicine. Sodium Intake in Populations: Assessment of Evidence. Washington, DC: National Academies Press; 2013.
   Google Scholar
• U.S. Department of Health and Human Services, U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 8th ed. Washington, DC: United States Department of Agriculture; 2015.
   Google Scholar
• US Food and Drug Administration. Voluntary sodium reduction goals: target mean and upper bound concentrations for sodium in commercially processed, packaged, and prepared foods: guidance for industry. 2021. Available from: https://www.fda.gov/media/98264/download. Accessed December 8, 2021.
   Google Scholar
• National Academies of Sciences Engineering and Medicine. Dietary Reference Intakes for Sodium and Potassium. Washington, DC: National Academies Press; 2019.
   Google Scholar
• United States Department of Agriculture. Scientific report of the 2015 dietary guidelines advisory committee. Washington, DC: United States Department of Health and Human Services; United States Department of Agriculture; 2015.
   Google Scholar
• Quader ZS, Zhao L, Gillespie C, et al. Sodium intake among persons aged ≥2 years - United States, 2013–2014. MMWR Morb Mortal Wkly Rep. 2017;66(12):238–324. doi:10.15585/mmwr.mm6612a3
   Web of Science ®Google Scholar
• Strazzullo P, D’Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567. doi:10.1136/bmj.b4567
   PubMed Web of Science ®Google Scholar
• Ma Y, He FJ, Sun Q, et al. 24-Hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med. 2022;386(3):252–263. doi:10.1056/NEJMoa2109794
   PubMed Web of Science ®Google Scholar
• Gardener H, Rundek T, Wright CB, Elkind MS, Sacco RL. Dietary sodium and risk of stroke in the Northern Manhattan study. Stroke. 2012;43(5):1200–1205. doi:10.1161/STROKEAHA.111.641043
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371(7):624–634. doi:10.1056/NEJMoa1304127
   PubMed Web of Science ®Google Scholar
• Chen C, Jenkins J, Zomorodi K, Skowronski R. Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in 2 open-label, randomized, crossover studies. Clin Transl Sci. 2021;14(6):2278–2287. doi:10.1111/cts.13087
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep. 2009;32(8):993–998. doi:10.1093/sleep/32.8.993
   PubMed Web of Science ®Google Scholar
• Kamal RM, van Noorden MS, Franzek E, Dijkstra BA, Loonen AJ, De Jong CA. The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: a review. Neuropsychobiology. 2016;73(2):65–80. doi:10.1159/000443173
   PubMed Web of Science ®Google Scholar
• U.S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42–49.
   PubMed Web of Science ®Google Scholar
• U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5(2):119–123. doi:10.1016/j.sleep.2003.11.002
   PubMed Web of Science ®Google Scholar
• U.S. Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26(1):31–35.
   PubMed Web of Science ®Google Scholar
• Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4):391–397. doi:10.5664/jcsm.26368
   PubMed Web of Science ®Google Scholar
• Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005;6(5):415–421. doi:10.1016/j.sleep.2005.03.010
   PubMed Web of Science ®Google Scholar
• Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939–946. doi:10.1093/sleep/29.7.939
   PubMed Web of Science ®Google Scholar
• Plazzi G, Ruoff C, Lecendreux M, et al. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. Lancet Child Adolesc Health. 2018;2(7):483–494. doi:10.1016/S2352-4642(18)30133-0
   PubMedGoogle Scholar
• Dauvilliers Y, Šonka K, Bogan RK, et al. Changes in cataplexy frequency in a clinical trial of lower-sodium oxybate with taper and discontinuation of other anticataplectic medications. CNS Drugs. 2022;36:633–647. doi:10.1007/s40263-022-00926-0
   PubMed Web of Science ®Google Scholar
• Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009;10(8):829–835. doi:10.1016/j.sleep.2009.05.004
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Roth T, Guinta D, Alvarez-Horine S, Dynin E, Black J. Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. Sleep Med. 2017;40:53–57. doi:10.1016/j.sleep.2017.07.030
   PubMed Web of Science ®Google Scholar
• Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6(6):596–602. doi:10.5664/jcsm.27994
   PubMed Web of Science ®Google Scholar
• Husain AM, Bujanover S, Ryan R, Scheckner B, Black J, Profant J. Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy. J Clin Sleep Med. 2020;16(9):1469–1474. doi:10.5664/jcsm.8530
   PubMed Web of Science ®Google Scholar
• Bogan RK, Foldvary-Schaefer N, Skowronski R, Chen A, Thorpy MJ. Long-term safety and tolerability during a clinical trial and open-label extension of lower-sodium oxybate in participants with narcolepsy with cataplexy. CNS Drugs. 2023;37(4):323–335. doi:10.1007/s40263-023-00992-y
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Arnulf I, Foldvary-Schaefer N, et al. Efficacy and safety of lower-sodium oxybate in an open-label titration period of a phase 3 clinical study in adults with idiopathic hypersomnia. Nat Sci Sleep. 2022;14:1901–1917. doi:10.2147/NSS.S369122
   PubMed Web of Science ®Google Scholar
• Morse AM, Dauvilliers Y, Arnulf I, et al. Long-term efficacy and safety of lower-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia. J Clin Sleep Med. 2023. July 6 Online Ahead of Print. doi:10.5664/jcsm.10698
   Web of Science ®Google Scholar
• Leary EB, Pfister C, Fuller DS, Macfadden W. Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from sodium oxybate (SEGUE) [poster 324]. Presented at: Annual Meeting of the Associated Professional Sleep Societies; Indianapolis, IN; 2023.
   Google Scholar
• Philip P, Chaufton C, Taillard J, et al. Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial. Sleep. 2014;37(3):483–487. doi:10.5665/sleep.3480
   PubMed Web of Science ®Google Scholar
• Sagaspe P, Micoulaud-Franchi JA, Coste O, et al. Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia. Sleep Med. 2019;55:1–5. doi:10.1016/j.sleep.2018.02.009
   PubMed Web of Science ®Google Scholar
• Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 2009;10(6):661–663. doi:10.1016/j.sleep.2008.05.012
   PubMed Web of Science ®Google Scholar
• Schinkelshoek MS, Smolders IM, Donjacour CE, et al. Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1. J Sleep Res. 2019;28(3):e12684. doi:10.1111/jsr.12684
   PubMed Web of Science ®Google Scholar
• Foldvary-Schaefer N, Skowronski R, Hickey L, Chen A, Measey TJ, Dauvilliers Y. Weight changes during treatment with lower-sodium oxybate in a phase 3 clinical study in patients with narcolepsy [poster 136]. Presented at: Annual Meeting of the Associated Professional Sleep Societies; Charlotte, NC; 2022.
   Google Scholar
• Dauvilliers Y, Chandler P, Hickey L, Chen A, Steininger T, Foldvary-Schaefer N. Weight changes during treatment with lower-sodium oxybate in a phase 3 clinical study in patients with idiopathic hypersomnia [poster 132]. Presented at: Annual Meeting of the Associated Professional Sleep Societies; Charlotte, NC; 2022.
   Google Scholar
• Donjacour CE, Aziz NA, Overeem S, Kalsbeek A, Pijl H, Lammers GJ. Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study. Sleep. 2014;37(4):795–801. doi:10.5665/sleep.3592
   PubMed Web of Science ®Google Scholar
• Cohen A, Mandrekar J, St Louis EK, Silber MH, Kotagal S. Comorbidities in a community sample of narcolepsy. Sleep Med. 2018;43:14–18. doi:10.1016/j.sleep.2017.11.1125
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Jaussent I, Krams B, et al. Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS One. 2012;7(6):e38977. doi:10.1371/journal.pone.0038977
   PubMed Web of Science ®Google Scholar
• Hermida RC, Crespo JJ, Otero A, et al. Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention. Eur Heart J. 2018;39(47):4159–4171. doi:10.1093/eurheartj/ehy475
   PubMed Web of Science ®Google Scholar
• Hozawa A, Inoue R, Ohkubo T, et al. Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study. J Hypertens. 2008;26(8):1571–1576. doi:10.1097/HJH.0b013e3283041172
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20(11):2183–2189. doi:10.1097/00004872-200211000-00017
   PubMed Web of Science ®Google Scholar
• Grandner MA, Jackson NJ, Pak VM, Gehrman PR. Sleep disturbance is associated with cardiovascular and metabolic disorders. J Sleep Res. 2012;21(4):427–433. doi:10.1111/j.1365-2869.2011.00990.x
   PubMed Web of Science ®Google Scholar
• Bock J, Covassin N, Somers V. Excessive daytime sleepiness: an emerging marker of cardiovascular risk. Heart. 2022;108(22):1761–1766. doi:10.1136/heartjnl-2021-319596
   PubMed Web of Science ®Google Scholar
• Bigalke JA, Shan Z, Carter JR. Orexin, sleep, sympathetic neural activity, and cardiovascular function. Hypertension. 2022;79(12):2643–2655. doi:10.1161/HYPERTENSIONAHA.122.19796
   PubMed Web of Science ®Google Scholar
• Jacobs DR Jr, Woo JG, Sinaiko AR, et al. Childhood cardiovascular risk factors and adult cardiovascular events. N Engl J Med. 2022;386(20):1877–1888. doi:10.1056/NEJMoa2109191
   PubMed Web of Science ®Google Scholar
• Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ. 2013;346:f1326. doi:10.1136/bmj.f1326
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;362(7):590–599. doi:10.1056/NEJMoa0907355
   PubMed Web of Science ®Google Scholar
• Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885–888. doi:10.1136/bmj.39147.604896.55
   PubMed Web of Science ®Google Scholar
• Whelton PK, Appel L, Charleston J, et al. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. results of the trials of hypertension prevention, phase I. JAMA. 1992;267(9):1213–1220. doi:10.1001/jama.1992.03480090061028
   PubMed Web of Science ®Google Scholar
• Whelton PK, Appel L, Charleston J, et al. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. Arch Intern Med. 1997;157(6):657–667.
   PubMedGoogle Scholar
• Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3–10. doi:10.1056/NEJM200101043440101
   PubMed Web of Science ®Google Scholar
• Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021;385(12):1067–1077. doi:10.1056/NEJMoa2105675
   PubMed Web of Science ®Google Scholar
• Zeng C, Rosenberg L, Li X, et al. Sodium-containing Acetaminophen and cardiovascular outcomes in individuals with and without hypertension. Eur Heart J. 2022;43(18):1743–1755. doi:10.1093/eurheartj/ehac059
   PubMed Web of Science ®Google Scholar
• George J, Majeed W, Mackenzie IS, Macdonald TM, Wei L. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. BMJ. 2013;347:f6954. doi:10.1136/bmj.f6954
   PubMed Web of Science ®Google Scholar
• Benitez-Camps M, Morros Padros R, Pera-Pujadas H, et al. Effect of effervescent paracetamol on blood pressure: a crossover randomized clinical trial. J Hypertens. 2018;36(8):1656–1662. doi:10.1097/HJH.0000000000001733
   PubMed Web of Science ®Google Scholar
• Ubeda A, Llopico J, Sanchez MT. Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication. Pharmacoepidemiol Drug Saf. 2009;18(5):417–419. doi:10.1002/pds.1701
   PubMed Web of Science ®Google Scholar
• Clinical superiority findings; 2021. Available from: https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings. Accessed July 9, 2021.
   Google Scholar
• Bosco A, Lopez R, Barateau L, et al. Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. Neurology. 2018;90(6):e479–e491. doi:10.1212/WNL.0000000000004911
   PubMed Web of Science ®Google Scholar
• Life’s Essential 8; 2022. Available from: https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8. Accessed January 16, 2023.
   Google Scholar
• Strunc MJ, Black J, Lillaney P, et al. The Xyrem(®) (sodium oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: results from 2016 to 2017. Drugs Real World Outcomes. 2021;8(1):15–28. doi:10.1007/s40801-020-00223-6
   PubMedGoogle Scholar
• Molina BSG, Kipp HL, Joseph HM, et al. Stimulant diversion risk among college students treated for ADHD: primary care provider prevention training. Acad Pediatr. 2020;20(1):119–127. doi:10.1016/j.acap.2019.06.002
   PubMed Web of Science ®Google Scholar
• Boucetta S, Montplaisir J, Zadra A, et al. Altered regional cerebral blood flow in idiopathic hypersomnia. Sleep. 2017;40(10). doi:10.1093/sleep/zsx140
   PubMed Web of Science ®Google Scholar
• Pomares FB, Boucetta S, Lachapelle F, et al. Beyond sleepy: structural and functional changes of the default-mode network in idiopathic hypersomnia. Sleep. 2019;42(11). doi:10.1093/sleep/zsz156
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Evangelista E, de Verbizier D, Barateau L, Peigneux P. [18F]Fludeoxyglucose-positron emission tomography evidence for cerebral hypermetabolism in the awake state in narcolepsy and idiopathic hypersomnia. Front Neurol. 2017;8:350. doi:10.3389/fneur.2017.00350
   PubMed Web of Science ®Google Scholar
• Scherfler C, Frauscher B, Schocke M, et al. White and gray matter abnormalities in narcolepsy with cataplexy. Sleep. 2012;35(3):345–351. doi:10.5665/sleep.1692
   PubMed Web of Science ®Google Scholar
• Huang X, Tang S, Lyu X, Yang C, Chen X. Structural and functional brain alterations in obstructive sleep apnea: a multimodal meta-analysis. Sleep Med. 2019;54:195–204. doi:10.1016/j.sleep.2018.09.025
   PubMed Web of Science ®Google Scholar